✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key takeaways
- Mazdutide is a GLP-1 / glucagon dual agonist. Developed primarily by Innovent Biologics in China under licence from Eli Lilly.
- Phase 2 readout: -11.1% mean weight loss at 24 weeks at the 6 mg weekly dose in Chinese adults with obesity.
- Phase 3 DREAMS program is approaching NMPA submission. The molecule is the regulatory-pathway-leading dual GLP-1/glucagon agonist in the Chinese / Asian market.
- Structurally similar to oxyntomodulin, a naturally occurring proglucagon-derived peptide with intrinsic GLP-1 / glucagon dual-receptor activity.
- This guide covers mechanism, regulatory pathway, and research applicability for the Asian-market-leading dual agonist.
Mazdutide Peptide: GLP-1 / Glucagon Dual Agonist Research Guide
Mazdutide (Innovent Biologics IBI362) is the GLP-1 / glucagon dual agonist with the most advanced Chinese regulatory pathway in the incretin class. The molecule is developed in collaboration with Eli Lilly under a licensing arrangement that gives Innovent Chinese commercial rights and Lilly rest-of-world. For obesity-pharma research focused on the Chinese / Asian population landscape, mazdutide is the regulatory-grade reference compound. This guide covers the molecule, the Phase 2/3 trial data, and where it fits in the broader research landscape.
What is mazdutide
Mazdutide is a synthetic peptide structurally similar to oxyntomodulin — the naturally occurring proglucagon-derived peptide with intrinsic GLP-1 receptor and glucagon receptor activity. The synthetic molecule is engineered with acylation modifications supporting albumin binding for extended plasma residence (half-life ~8 days, supporting weekly subcutaneous dosing). The receptor activity profile retains the dual GLP-1 / glucagon agonism of native oxyntomodulin while shedding the rapid enzymatic degradation that limits oxyntomodulin’s direct research applicability.
Mechanism
The dual-receptor architecture combines two complementary weight-loss mechanisms. GLP-1 agonism drives appetite suppression (hypothalamic and vagal satiety circuits) and slowed gastric emptying. Glucagon agonism adds hepatic energy expenditure — glucagon-receptor activation increases hepatic glucose output and direct hepatic thermogenesis, raising basal metabolic rate via a different pathway than appetite suppression. The combination produces deeper weight loss than GLP-1 monoagonism by adding the metabolic-rate arm.
Mazdutide skips the GIP arm that tirzepatide includes — the architectural difference vs tirzepatide is “glucagon instead of GIP” rather than “GIP plus glucagon” (which is retatrutide). The cleanness of this design enables specific mechanism research: comparing mazdutide with tirzepatide isolates the GIP vs glucagon contribution to dual-agonist depth-of-effect.
Research applications
The primary research applicability is in the GLP-1 / glucagon dual-agonist mechanism space. Active research scenarios include: regulatory-precedent dual-agonist research in the Chinese / Asian context (mazdutide is the regulatory-pathway-leading molecule in this region); GIP vs glucagon arm-isolation research (mazdutide and tirzepatide head-to-head); MASH / fatty-liver research (the glucagon arm produces hepatic-lipid effects); and Phase 3 program comparator research.
Research dosing
Phase 2 / 3 protocols titrate from 1.5 mg weekly SC through 3 mg to a 6 mg maintenance dose, with each step lasting ~4 weeks. The Phase 2 top-dose readout (-11.1% at 24 wk) used 6 mg weekly. Phase 3 DREAMS may evaluate higher doses; the published protocol details are not yet fully disclosed.
Side-effect profile
Class-level incretin signature: nausea (most prominent), occasional vomiting, GI side effects most pronounced in the first 4-8 weeks of each dose step. Glucagon-arm-specific considerations include modest blood-pressure effects in some published research, slight elevation in fasting glucose in dose-finding studies (counterbalanced by GLP-1’s insulin-secretion-amplifying effect), and the general weight-loss-class consideration of gallstone risk with rapid weight loss.
Comparator and stacking
The direct dual-glucagon-class comparator is survodutide (Boehringer Ingelheim) — both molecules are GLP-1 / glucagon dual agonists developed in parallel. See: Survodutide vs Tirzepatide for the survodutide context. For the broader incretin cluster, see Mazdutide vs Retatrutide (dual vs triple agonist) and Best peptides for fat loss.
Storage and reconstitution
Lyophilized vials at -20 °C long-term, 2-8 °C working stock. Reconstitute with bacteriostatic water. Reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw.
Safety and regulatory status
Mazdutide has no FDA / EMA / MHRA approval. The molecule is approaching NMPA (China) regulatory review through the Phase 3 DREAMS program. The research-grade compound on the catalogue is sold for in-vitro laboratory research and analytical reference use only. None of this constitutes medical advice.
FAQ
How is mazdutide different from survodutide?
Both are GLP-1 / glucagon dual agonists. Different developers (Innovent / Lilly for mazdutide; Boehringer Ingelheim for survodutide). Different regulatory pathways (NMPA-led for mazdutide, FDA / EMA-led for survodutide). Phase 2 effect sizes broadly similar with mazdutide’s readout limited by shorter trial duration (-11.1% at 24 wk vs survodutide -18.7% at 46 wk).
Why is mazdutide developed primarily in China?
The Eli Lilly licensing structure: Innovent has Chinese commercial rights and developed the Phase 1/2/3 program in Chinese clinical-trial centres; Lilly retains rest-of-world rights. The development sequencing was chosen for commercial and regulatory-pathway considerations rather than mechanism reasons.
Will mazdutide get FDA approval?
Unclear as of catalogue date. The Lilly licensing structure could route the molecule into the FDA pathway, but no public timeline exists. The molecule’s strongest near-term regulatory case is NMPA approval through the DREAMS Phase 3 program.
How does mazdutide compare to retatrutide?
Both have glucagon arms; retatrutide adds GIP for triple agonism. Mazdutide -11.1% at 24 wk vs retatrutide -24.2% at 48 wk; the triple agonist produces deeper readout at longer timeframe. See: Mazdutide vs Retatrutide.
What’s the typical research dose?
1.5 mg weekly SC titrating through 3 mg to a 6 mg maintenance dose, with each step lasting approximately 4 weeks. Phase 3 may evaluate higher doses; the published protocol details are not yet fully disclosed.
Storage protocol?
Lyophilized at -20 °C long-term, 2-8 °C working; reconstituted at 2-8 °C use within 30 days; protect from light; never freeze-thaw.
Bottom line
Mazdutide is the regulatory-pathway-leading GLP-1 / glucagon dual agonist in the Chinese / Asian market. The dual-receptor architecture combines appetite suppression (GLP-1) with hepatic energy expenditure (glucagon) for deeper effect than GLP-1 monoagonism. The Phase 2 readout (-11.1% at 24 wk) is limited by the shorter trial duration relative to survodutide and retatrutide; Phase 3 DREAMS data will clarify the comparative positioning. For research-protocol design, mazdutide is the dual-glucagon-class molecule with the most-advanced Chinese regulatory pathway.
Related research guides
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.